Home Headline News Jaguar Health (NASDAQ:JAGX) Stock Is on the Move

Jaguar Health (NASDAQ:JAGX) Stock Is on the Move

by S. Jack Heffernan Ph.D

$JAGX #JaguarHealth #USA #Stocks #Nasdaq #Market #Trading

Jaguar Health
Ticker: NASDAQ:JAGX
Price: $1.95

Jaguar Health News

Jaguar Health is a California-based biopharmaceutical company that specializes in treating gastrointestinal conditions. It focuses on both humans and animals, although its treatments for two-legged patients are farther along in the pipeline. In fact, news that it was hoping to expand the use of its drug Mytesi is what sent JAGX stock soaring in December.

With that in mind, here are a few things to know about Jaguar Health:

  • Jaguar Health says it focuses on developing sustainably derived gastrointestinal products. Specifically, it looks to develop plant-based prescription medicines.
  • The company also has a wholly owned subsidiary, Napo Pharmaceuticals.
  • Napo specifically works to develop and commercialize treatments based on rainforest-area plants.
  • Investors should note that the main Jaguar product is Mytesi, which has U.S. Food and Drug Administration approval.
  • Right now, Mytesi is used as an antidiarrheal in adult patients with HIV/AIDS who are on antiretroviral therapies.
  • Earlier in December, Jaguar Health announced a new financing deal to help fund a few regulatory actions.
  • Importantly, Jaguar Health thinks Mytesi works as an antidiarrheal for other conditions.
  • Specifically, it is hoping to receive regulatory approval to market Mytesi as an antidiarrheal for cancer therapy-induced diarrhea.
  • Napo Pharmaceuticals is also making big moves.
  • Specifically, the company is working to expand into Europe as Napo EU.
  • There, Napo Pharmaceuticals is also discussing a SPAC merger to take its new Napo EU public.
  • Additionally, Napo Pharmaceuticals believes Mytesi could potentially work as an antidiarrheal for patients with long-term Covid-19 symptoms.

Business Summary

Jaguar Health, Inc. is a natural-products pharmaceuticals company.

The Company is focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis.

The Company, through its subsidiary Napo Pharmaceuticals, Inc., is focused on developing and commercializing human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas.

Its Mytesi is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with human immunodeficiency virus HIV/ acquired immune deficiency syndrome (AIDS) on antiretroviral therapy. Its other products include Canalevia, Equilevia, Neonorm Calf and Neonorm Foal.

Price Performance

Relative Valuation

Technical Indicators

Overall, the bias in prices is: Upwards.

Note: this chart shows extraordinary price action to the upside.

By the way, prices are vulnerable to a correction towards 0.55.

The projected upper bound is: 2.51.

The projected lower bound is: 1.45.

The projected closing price is: 1.98.

Candlesticks

A black body occurred (because prices closed lower than they opened).
During the past 10 bars, there have been 5 white candles and 5 black candles. During the past 50 bars, there have been 17 white candles and 33 black candles for a net of 16 black candles.

A long upper shadow occurred. This is typically a bearish signal (particularly when it occurs near a high price level, at resistance level, or when the security is overbought).

A rising window occurred (where the top of the previous shadow is below the bottom of the current shadow). This usually implies a continuation of a bullish trend. There have been 3 rising windows in the last 50 candles–this makes the current rising window even more bullish.

Momentum Indicators

Momentum is a general term used to describe the speed at which prices move over a given time period. Generally, changes in momentum tend to lead to changes in prices. This expert shows the current values of four popular momentum indicators.

Stochastic Oscillator

One method of interpreting the Stochastic Oscillator is looking for overbought areas (above 80) and oversold areas (below 20). The Stochastic Oscillator is 66.5375. This is not an overbought or oversold reading. The last signal was a buy 13 period(s) ago.

Relative Strength Index (RSI)

The RSI shows overbought (above 70) and oversold (below 30) areas. The current value of the RSI is 82.39. This is where it usually tops. The RSI usually forms tops and bottoms before the underlying security. A buy or sell signal is generated when the RSI moves out of an overbought/oversold area. The last signal was a sell 6 period(s) ago.

MACD

The Moving Average Convergence/Divergence indicator (MACD) gives signals when it crosses its 9 period signal line. The last signal was a buy 7 period(s) ago.

Rex Takasugi – TD Profile

JAGUAR HELTH ORD closed up 0.170 at 1.950. Volume was 897% above average (trending) and Bollinger Bands were 564% wider than normal.

Open    High    Low    Close    Volume
2.210   2.990   1.890  1.950    334,251,584
Technical Outlook
Short Term:        Neutral
Intermediate Term: Bullish
Long Term:         Bullish
Moving Averages: 10-period     50-period      200-period
Close:           0.92          0.40           0.46
Volatility:      745           409            234
Volume:          182,419,424   55,348,944     17,208,800

Short-term traders should pay closer attention to buy/sell arrows while intermediate/long-term traders should place greater emphasis on the Bullish or Bearish trend reflected in the lower ribbon.

Summary

JAGUAR HELTH ORD gapped up today (bullish) on heavy volume. Possibility of a Breakaway Gap which usually signifies the beginning of a major market move. Four types of price gaps exist – Common, Breakaway, Runaway, and Exhaustion. Gaps acts as support/resistance.

JAGUAR HELTH ORD is currently 319.6% above its 200-period moving average and is in an upward trend. Volatility is extremely high when compared to the average volatility over the last 10 periods. There is a good possibility that volatility will decrease and prices will stabilize in the near term. Our volume indicators reflect very strong flows of volume into JAGX.O (bullish). Our trend forecasting oscillators are currently bullish on JAGX.O and have had this outlook for the last 24 periods. Our momentum oscillator is currently indicating that JAGX.O is currently in an overbought condition. The security price has set a new 14-period high while our momentum oscillator has not. This is a bearish divergence.

You may also like

logo-white

Your Trusted Source for Capital Markets & Related News

© 2024 LiveTradingNews.com – For The Traders, By The Traders – All Right Reserved.

The information contained on this website shall not be construed as (i) an offer to purchase or sell, or the solicitation of an offer to purchase or sell, any securities or services, (ii) investment, legal, business or tax advice or an offer to provide such advice, or (iii) a basis for making any investment decision. An offering may only be made upon a qualified investor’s receipt not via this website of formal materials from the Knightsbridge an offering memorandum and subscription documentation (“offering materials”). In the case of any inconsistency between the information on this website and any such offering materials, the offering materials shall control. Securities shall not be offered or sold in any jurisdiction in which such offer or sale would be unlawful unless the requirements of the applicable laws of such jurisdiction have been satisfied. Any decision to invest in securities must be based solely upon the information set forth in the applicable offering materials, which should be read carefully by qualified investors prior to investing. An investment with Knightsbridge is not suitable or desirable for all investors; investors may lose all or a portion of the capital invested. Investors may be required to bear the financial risks of an investment for an indefinite period of time. Qualified investors are urged to consult with their own legal, financial and tax advisors before making any investment. Knightsbridge is a private investment firm that offers investment services to Qualified Investors, Members and Institutions ONLY. Qualified Investors are defined as individuals who have met those Qualifications in the relevant jurisdictions. Members are defined as individuals who have been accepted into the Knightsbridge membership program. Institutions are defined as entities such as banks, pension funds, and hedge funds. If you are not a Qualified Investor, Member or Institution, you are not eligible to invest with Knightsbridge. All investments involve risk, and there is no guarantee of profit. You may lose some or all of your investment. Past performance is not indicative of future results. Knightsbridge is not a registered investment advisor, and this disclaimer should not be construed as investment advice. Please consult with a qualified financial advisor before making any investment decisions. By accessing this website, you agree to the terms of this disclaimer. Thank you for your interest in Knightsbridge.